As per the letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board meeting on May 28, 2025 approved Dr. Agarwal's Eye Hospital's audited FY25 results. Revenue from operations grew ~24.4% YoY to Rs. 397.15 cr (FY24: Rs. 319.30 cr), while net profit rose ~17.9% to Rs. 54.65 cr (FY24: Rs. 46.36 cr). EBITDA expanded to Rs. 123.59 cr from Rs. 96.03 cr, with margin improving slightly to about 31%. The Board recommended a final dividend of Rs. 3.50 per share, taking total FY25 dividend to Rs. 6.00/share (60% payout, including the interim Rs. 2.50 paid earlier). Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion. The company appointed M/s. S.R. Batliboi & Associates LLP as the new statutory auditor for a 5-year term (FY26–FY30), replacing Deloitte. Promoter directors Dr. Amar Agarwal (CMD) and Dr. Athiya Agarwal (Whole-time Director) were reappointed for 3 years from October 1, 2025.
Strong top-line growth and a generous 60% dividend payout are positives for shareholders. PAT growth trailed revenue due to higher input and employee costs, but overall profitability remains healthy. The auditor change is a routine rotation at end of term, not a governance red flag.